Latest Advances In Applied Nanotechnology For Formulating Better Amorphous Solid Dispersions And Monoclonal Antibodies

Leading-edge nanotechnologies are revolutionizing the field of biologics by opening doors to entirely new formulation possibilities. This translates to a wider range of products for patients, with benefits for both the patient experience and the competitive edge of biopharmaceutical innovators.

Nanoform's advanced process shows promise for directly formulating biologics into suspensions for long-acting injections or inhaled delivery. This holds the potential for creating highly concentrated formulations that could allow patients to switch from intravenous (IV) administration to more convenient subcutaneous injections. Additionally, these nanoformed biologics could pave the way for delivering macromolecules deep into the lungs.

Additionally, new data from both in vitro and in vivo studies suggests that nanoformed formulations may outperform existing options like amorphous solid dispersions (ASDs). Nanoformed formulations could potentially offer equivalent bioavailability but with fewer doses, smaller pills, and an overall reduction in the burden on patients. This not only improves patient convenience but also presents strong intellectual property (IP) opportunities. As an example, clinical trials demonstrated that a single 160mg tablet containing nanoformed enzalutamide achieved the same level of drug exposure as four 40mg Xtandi® tablets (which use spray dried dispersion). This points towards a significantly more patient-centric treatment approach.

This webinar provides key takeaways:

• Discover how the latest advancements in nanotechnology can enhance your formulations, including those for monoclonal antibodies (mAbs).
• Explore new data on nanotechnology-based formulations designed for various dosage forms and delivery routes, including oral administration, long-acting injections, inhalation, and ophthalmic applications.
• Learn strategies to overcome challenges associated with drug loading and pill burden that are commonly encountered with ASD formulations.